US EditionPublished • loading... • Updated
It Has Invested 600 Million Euros Since 2020: in Dunkirk, Astrazeneca Decarbonizes the Production of Inhalers for Respiratory Diseases
Summary by usinenouvelle.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Since its establishment in 1990, the AstraZeneca plant in Dunkirk (North) has become the world leader in the production of respiratory inhalers. More than 60 million units are produced here every year, with the ambition to reach 100 million per year by 2030, to treat in particular asthma and chronic obstructive bronchopneumopathy. 99% of the production goes to export to 75 countries, of which "60% only for China and the United States", says Welh…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
